Drug Approval | November 21, 2023
GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia
Decision on EU marketing authorisation expected for momelotinib by early 2024
Decision on EU marketing authorisation expected for momelotinib by early 2024
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Collaboration enables Brenntag to serve pharma customers in EMEA with chromatography silica gels
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Yesafili, received marketing authorization approval from the European Commission for the European Union
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
European operations' revenue grew 58.4% to Rs 599.7 crore
US business grew by +12.8% YoY
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Subscribe To Our Newsletter & Stay Updated
